PMID- 33869012
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210421
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Decitabine With or Without Micro-Transplantation for the Treatment of 
      Intermediate or High-Risk Myelodysplastic Syndrome: A Chinese Single-Center 
      Retrospective Study of 22 Patients.
PG  - 628127
LID - 10.3389/fonc.2021.628127 [doi]
LID - 628127
AB  - The treatment outcomes of intermediate or high-risk myelodysplastic syndrome 
      (MDS) remain unsatisfactory. This study was designed to evaluate the safety and 
      efficacy of human leukocyte antigen (HLA)-mismatched hematopoietic stem cell 
      micro-transplantation (MST) in patients with MDS. A total of 22 patients with 
      MDS, ranging between the ages of 39 and 74, were enrolled in this study. Eleven 
      patients were given decitabine (DAC), a DNA methyltransferase inhibitor, combined 
      with HLA-mismatched MST (MST-DAC group), and the remaining patients were given 
      decitabine only (DAC group). The median overall survival (OS) of the MST-DAC 
      group was higher than that of the DAC group (24 vs. 14.3 months; HR 0.32; 95% CI: 
      0.11-0.96; p = 0.04), although it is a study with small samples. The overall 
      response rate (ORR), marrow complete remission (mCR), plus hematological 
      improvement (HI) rates of the MST-DAC group were higher than that of the DAC 
      group (81.8 vs. 54.5%, p = 0.36; 63.6 vs. 27.3%, p = 0.09, respectively); 
      however, there were no statistical differences between the two groups, which may 
      be attributed to the limited number of cases evaluated in this study. No 
      graft-vs.-host disease was observed in the MST-DAC group. Patients in the MST-DAC 
      group demonstrated a slightly lower incidence of hematological and 
      non-hematological adverse events (AEs). DAC combined with HLA-mismatched MST may 
      provide a novel, effective, and safe treatment for use in intermediate or 
      high-risk MDS pathologies.
CI  - Copyright (c) 2021 Li, Li, Geng, Chen, Wu, Deng, Chen, Lu, Weng and Du.
FAU - Li, MinMing
AU  - Li M
AD  - Department of Hematology, Guangdong Provincial People's Hospital, Guangdong 
      Academy of Medical Sciences, Guangzhou, China.
FAU - Li, Chao
AU  - Li C
AD  - Department of Hematology, Guangdong Provincial People's Hospital, Guangdong 
      Academy of Medical Sciences, Guangzhou, China.
AD  - Department of Hematology, School of Medicine, Guangdong Provincial People's 
      Hospital, Guangdong Academy of Medical Sciences, South China University of 
      Technology, Guangzhou, China.
FAU - Geng, SuXia
AU  - Geng S
AD  - Department of Hematology, Guangdong Provincial People's Hospital, Guangdong 
      Academy of Medical Sciences, Guangzhou, China.
FAU - Chen, XiaoMei
AU  - Chen X
AD  - Department of Hematology, Guangdong Provincial People's Hospital, Guangdong 
      Academy of Medical Sciences, Guangzhou, China.
FAU - Wu, Ping
AU  - Wu P
AD  - Department of Hematology, Guangdong Provincial People's Hospital, Guangdong 
      Academy of Medical Sciences, Guangzhou, China.
FAU - Deng, ChengXin
AU  - Deng C
AD  - Department of Hematology, Guangdong Provincial People's Hospital, Guangdong 
      Academy of Medical Sciences, Guangzhou, China.
FAU - Chen, XiaoFang
AU  - Chen X
AD  - Department of Hematology, Guangdong Provincial People's Hospital, Guangdong 
      Academy of Medical Sciences, Guangzhou, China.
FAU - Lu, ZeSheng
AU  - Lu Z
AD  - Department of Hematology, Guangdong Provincial People's Hospital, Guangdong 
      Academy of Medical Sciences, Guangzhou, China.
FAU - Weng, JianYu
AU  - Weng J
AD  - Department of Hematology, Guangdong Provincial People's Hospital, Guangdong 
      Academy of Medical Sciences, Guangzhou, China.
AD  - Department of Hematology, School of Medicine, Guangdong Provincial People's 
      Hospital, Guangdong Academy of Medical Sciences, South China University of 
      Technology, Guangzhou, China.
FAU - Du, Xin
AU  - Du X
AD  - Department of Hematology, Guangdong Provincial People's Hospital, Guangdong 
      Academy of Medical Sciences, Guangzhou, China.
AD  - Department of Hematology, School of Medicine, Guangdong Provincial People's 
      Hospital, Guangdong Academy of Medical Sciences, South China University of 
      Technology, Guangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20210331
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8044401
OTO - NOTNLM
OT  - HLA-mismatched micro-transplantation
OT  - chronic myelomonocytic leukemia
OT  - decitabine
OT  - myelodysplastic syndromes
OT  - overall survival
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/04/20 06:00
MHDA- 2021/04/20 06:01
PMCR- 2021/01/01
CRDT- 2021/04/19 06:32
PHST- 2020/11/11 00:00 [received]
PHST- 2021/02/08 00:00 [accepted]
PHST- 2021/04/19 06:32 [entrez]
PHST- 2021/04/20 06:00 [pubmed]
PHST- 2021/04/20 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.628127 [doi]
PST - epublish
SO  - Front Oncol. 2021 Mar 31;11:628127. doi: 10.3389/fonc.2021.628127. eCollection 
      2021.